These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16711515)
21. Gastrin-releasing peptide: predictor of castration-resistant prostate cancer? Heinrich E; Probst K; Michel MS; Trojan L Prostate; 2011 May; 71(6):642-8. PubMed ID: 20945407 [TBL] [Abstract][Full Text] [Related]
22. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350 [TBL] [Abstract][Full Text] [Related]
23. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996 [TBL] [Abstract][Full Text] [Related]
30. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569 [TBL] [Abstract][Full Text] [Related]
31. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. Wu JT; Astill ME; Liu GH; Stephenson RA J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665 [TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329 [TBL] [Abstract][Full Text] [Related]
33. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024 [TBL] [Abstract][Full Text] [Related]
34. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L J Urol; 2007 Sep; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319 [TBL] [Abstract][Full Text] [Related]
35. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer. Di Silverio F; Sciarra A J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782 [TBL] [Abstract][Full Text] [Related]
36. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. Wu JT; Wu TL; Chang CP; Tsao KC; Sun CF J Clin Lab Anal; 1999; 13(6):308-11. PubMed ID: 10633300 [TBL] [Abstract][Full Text] [Related]
37. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344 [TBL] [Abstract][Full Text] [Related]
38. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Ahel MZ; Kovacic K; Tarle M Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214 [TBL] [Abstract][Full Text] [Related]
39. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443 [TBL] [Abstract][Full Text] [Related]
40. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer. Cerulli C; Sciarra A; Salvatori G; Di Silverio F Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]